Last reviewed · How we verify
Medice Arzneimittel Pütter GmbH & Co KG — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Vitamin B12, Vitamin B6, Folic acid | Vitamin B12, Vitamin B6, Folic acid | marketed | Vitamin supplement / B-complex combination | Nutritional deficiency / Cardiovascular / Neurology | ||
| Benzalkonium Chloride-Benzocaine Topical | Benzalkonium Chloride-Benzocaine Topical | marketed | Topical antimicrobial-anesthetic combination | Bacterial cell membranes (benzalkonium); sodium channels (benzocaine) | Dermatology / Topical antisepsis |
Therapeutic area mix
- Dermatology / Topical antisepsis · 1
- Nutritional deficiency / Cardiovascular / Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Medice Arzneimittel Pütter GmbH & Co KG:
- Medice Arzneimittel Pütter GmbH & Co KG pipeline updates — RSS
- Medice Arzneimittel Pütter GmbH & Co KG pipeline updates — Atom
- Medice Arzneimittel Pütter GmbH & Co KG pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Medice Arzneimittel Pütter GmbH & Co KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medice-arzneimittel-p-tter-gmbh-co-kg. Accessed 2026-05-17.